BioPharmSignal logoBioPharmSignal

Biotech News

Zura Bio to Participate in Upcoming Investor Conferences

Zura Bio (ZURA)Zura BioCompany update

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 2, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

Related news

ZURAZura Bio2026-08-21 23:57 EST

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZURAZura Bio2026-06-29 11:30 EST

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

APGEApogee Therapeutics2026-05-28 20:01 EST

Apogee Therapeutics to Participate in Upcoming June Conferences

XGNExagen2026-07-28 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conference

KNSAKiniksa2026-05-29 20:01 EST

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

ARGXArgenx2026-05-27 05:00 EST

argenx to Present at Upcoming Investor Conferences

IFRXInflarx NV2026-08-20 11:30 EST

InflaRx Announces Participation in September Investor Conferences

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

AVTXAvalo Therapeutics2026-07-07 11:00 EST

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

EQEquillium, Inc.2026-05-28 20:05 EST

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

View all latest news

Zura Bio

Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...

Recent company news

ZURAZura Bio2026-08-21 23:57 EST

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZURAZura Bio2026-08-11 11:30 EST

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

ZURAZura Bio2026-06-29 11:30 EST

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

ZURAZura Bio2026-05-14 11:30 EST

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ZURAZura Bio2026-05-13 11:30 EST

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

Stock data

Close
5.85 USD
Market cap
389.01M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States